A Phase 3 interventional study of Beriplex® P/N (Kcentra) and Fresh frozen plasma in Reversal of Coagulopathy, sponsored by CSL Behring. Completed at 30 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-04-06.
Sponsored by CSL Behring (part of CSL Limited) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Hemophilia B by CSL Limited — 4 open to participants now, 5 under way, 2 of them phase 3. Hemophilia B · CSL Limited.
Among the 18 studies in Hemophilia B by CSL Limited, this one has the largest enrollment of the 14 interventional ones that give a count, is the only one that started in 2009, is one of 8 in phase 3, and was the 2nd registered.
292 studies on the registry are indexed under Hemophilia B; 51 are open to participants now.
Browse Hemophilia B studies →4 of the 18 studies in Hemophilia B by CSL Limited are open now, in 12 countries. Recruiting first, the newest first:
CSL Behring · Sites in United States, Australia, Austria and 5 more countries
Ages 138 mo–206 mo · Men only
CSL Behring · Sites in United States, Australia, Brazil and 12 more countries
Ages 18+
CSL Behring · Sites in United States, Austria, Denmark and 4 more countries
Ages 18+
CSL Behring · Sites in United States, Belgium, Denmark and 5 more countries
Ages 18+ · Men only
By country, each count listing its studies:
Of the 30 Hemophilia B studies recruiting now, 17 (57%) set no upper age limit and 11 (37%) stop at 75 or younger; 16 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 5 · Phase 3 10
First in 2005; this study’s year is marked. 1 started in 2009.
This study's enrollment of 176 is above the median of 26 across 171 interventional studies indexed under Hemophilia B.
Median enrollment 26 across the 14 interventional studies, 139 across the 4 observational. Of the 13 that completed or were terminated, 8 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under CSL Behring, one of the names counted as CSL Limited. Under that name alone:
CSL Behring is the lead sponsor of 145 studies on the registry; 17 are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 17 (71%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 18 studies in Hemophilia B by CSL Limited, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate efficacy, safety and tolerance of Beriplex® P/N (Kcentra) compared with plasma in regard to rapid reversal of coagulopathy induced by vitamin K antagonists in subjects who require immediate correction of international normalized ratio (INR) because of emergency surgery.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
For subjects with intracranial hemorrhage with:
Subdural hematomas that:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: Beriplex® P/N (Kcentra)
Biological: Fresh frozen plasma
Drug pages: Prothrombin complex concentrate · Four-factor Prothrombin Complex Concentrate
Intravenous infusion, dosage depending on baseline INR, amount of coagulation factor IX and body-weight.
Also known as: Kcentra
Intravenous infusion, dosage depending on baseline INR and body weight
Percentage of Participants Achieving Hemostatic Efficacy During Surgery
Hemostatic efficacy was rated as excellent, good, or poor/none, based on prespecified definitions. Hemostatic efficacy was the binary endpoint of effective or non-effective hemostasis, where 'effective' was a hemostatic efficacy rating of "excellent" or "good," and 'non-effective' was a hemostatic efficacy rating of "poor/none".
Time frame: From the start of infusion until the end of surgery
Percentage of Participants Who Had a Rapid Decrease of the INR
A rapid decrease of the INR was defined as an INR ≤ 1.3 at 30 minutes after the end of infusion. The INR is a standard way to describe the time it takes for blood to clot; an INR range of 0.8 to 1.2 is considered normal for a healthy person who is not using oral anticoagulant therapy.
Time frame: 30 minutes after the end of infusion
Plasma Levels of Factors II, VII, IX, and X, Protein C, and Protein S
Plasma levels are presented as the percentage of normal at pre-infusion and 30 min and 24 h after the start of infusion. The plasma level assay results are reported as a potency relative to a standard, where 100% is considered to be normal.
Time frame: From pre-infusion until 24 h after the start of infusion
Transfusion of Packed Red Blood Cells (PRBCs) or Whole Blood
The total units of transfused PRBCs or whole blood
Time frame: From the start of surgery until 24 h after the start of surgery
Percentage of Participants With INR Correction at Various Times After the Start of Infusion
The time taken from the start of infusion to INR correction (defined as an INR ≤ 1.3) was recorded. The percentage of participants with INR correction was calculated at 0.5, 1, 3, 6, 12, and 24 h after the start of infusion.
Time frame: From the start of infusion until INR correction; calculated at 0.5, 1, 3, 6, 12, and 24 h after the start of infusion
Percentage of Participants Who Received Red Blood Cells
Red blood cells were PRBCs and whole blood
Time frame: From the start of surgery until 24 h after the start of surgery
Overall Treatment-emergent Adverse Events (TEAEs)
Number of participants with TEAEs. TEAEs were defined as adverse events that developed or worsened following exposure to investigational medicinal product. Treatment-related TEAEs were events whose relationship to study treatment was related, probably related, or possibly related in the opinion of the investigator. Treatment emergent adverse events with missing relationship were considered related to treatment. Serious TEAEs were treatment-emergent serious adverse events (SAEs).
Time frame: From the start of infusion up to the allowed time window of the Day 10 visit for non-serious AEs and from the start of infusion up to the allowed time window of the Day 45 visit for SAEs
| Milestone | Beriplex® P/N | Fresh Frozen Plasma |
|---|---|---|
| Started | 88 | 88 |
| Completed | 70 | 66 |
| Not completed | 18 | 22 |
| Withdrew: Death / serious adverse event | 4 | 6 |
| Withdrew: Withdrawal by subject | 6 | 4 |
| Withdrew: Lost to follow-up | 2 | 2 |
| Withdrew: Protocol violation | 1 | 7 |
| Withdrew: Surgery finished outside protocol window | 1 | 1 |
| Withdrew: Patient died outside sae report period | 1 | 0 |
| Withdrew: Patient did not attend scheduled visit | 2 | 1 |
| Withdrew: Patient did not have surgery | 1 | 1 |
Hemostatic efficacy was rated as excellent, good, or poor/none, based on prespecified definitions. Hemostatic efficacy was the binary endpoint of effective or non-effective hemostasis, where 'effective' was a hemostatic efficacy rating of "excellent" or "good," and 'non-effective' was a hemostatic efficacy rating of "poor/none".
| percentage of participants | Beriplex® P/N | Fresh Frozen Plasma |
|---|---|---|
| Percentage of Participants Achieving Hemostatic Efficacy During Surgery | 89.7 (83.3 to 96.1) | 75.3 (65.9 to 84.7) |
A rapid decrease of the INR was defined as an INR ≤ 1.3 at 30 minutes after the end of infusion. The INR is a standard way to describe the time it takes for blood to clot; an INR range of 0.8 to 1.2 is considered normal for a healthy person who is not using oral anticoagulant therapy.
| percentage of participants | Beriplex® P/N | Fresh Frozen Plasma |
|---|---|---|
| Percentage of Participants Who Had a Rapid Decrease of the INR | 55.2 (44.7 to 65.6) | 9.9 (3.4 to 16.4) |
Plasma levels are presented as the percentage of normal at pre-infusion and 30 min and 24 h after the start of infusion. The plasma level assay results are reported as a potency relative to a standard, where 100% is considered to be normal.
| percentage of normal | Beriplex® P/N | Fresh Frozen Plasma |
|---|---|---|
| Factor II, pre-infusion (n = 85; 79) | 32.0 ± 19.93 | 34.8 ± 26.19 |
| Factor II, 0.5 h after infusion start (n = 71; 73) | 84.5 ± 20.92 | 42.5 ± 25.71 |
| Factor II, 24 h after infusion start (n = 81; 74) | 81.4 ± 24.83 | 65.6 ± 23.68 |
| Factor VII, pre-infusion start (n = 85; 79) | 36.8 ± 59.27 | 31.1 ± 25.16 |
| Factor VII, 0.5h after infusion start (n = 71; 73) | 60.1 ± 44.91 | 41.6 ± 42.90 |
| Factor VII, 24 h after infusion start (n = 81; 74) | 85.5 ± 59.76 | 83.7 ± 58.90 |
| Factor IX, pre-infusion (n = 85; 79) | 48.1 ± 25.62 | 55.8 ± 30.50 |
| Factor IX, 0.5 h after infusion start (n = 71; 73) | 71.6 ± 25.38 | 56.2 ± 23.12 |
| Factor IX, 24 h after infusion start (n = 81; 74) | 85.2 ± 33.39 | 93.7 ± 34.25 |
| Factor X, pre-infusion (n = 85; 79) | 19.3 ± 19.32 | 20.8 ± 21.38 |
| Factor X, 0.5 h after infusion start (n = 71; 73) | 82.3 ± 23.33 | 29.8 ± 22.51 |
| Factor X, 24 h after infusion start (n = 81; 74) | 78.3 ± 25.62 | 60.2 ± 22.44 |
| Protein C, pre-infusion (n = 85; 78) | 48.8 ± 19.07 | 47.6 ± 21.38 |
| Protein C, 0.5 h after infusion start (n = 71; 73) | 97.1 ± 21.97 | 52.5 ± 18.69 |
| Protein C, 24 h after infusion start (n = 81; 74) | 87.3 ± 26.28 | 78.1 ± 24.80 |
| Protein S, pre-infusion (n = 85; 79) | 45.25 ± 18.498 | 46.18 ± 20.986 |
| Protein S, 0.5 h after infusion start (n = 72; 73) | 80.73 ± 31.489 | 55.82 ± 24.689 |
| Protein S, 24 h after infusion start (n = 82; 74) | 75.97 ± 36.449 | 69.32 ± 27.504 |
The total units of transfused PRBCs or whole blood
| units of PRBCs or whole blood | Beriplex® P/N | Fresh Frozen Plasma |
|---|---|---|
| Transfusion of Packed Red Blood Cells (PRBCs) or Whole Blood | 0.3 ± 0.90 | 0.4 ± 1.02 |
The time taken from the start of infusion to INR correction (defined as an INR ≤ 1.3) was recorded. The percentage of participants with INR correction was calculated at 0.5, 1, 3, 6, 12, and 24 h after the start of infusion.
| percentage of participants | Beriplex® P/N | Fresh Frozen Plasma |
|---|---|---|
| 0.5 h | 1 | 0 |
| 1 h | 54 | 0 |
| 3 h | 77 | 10 |
| 6 h | 81 | 20 |
| 12 h | 83 | 32 |
| 24 h | 87 | 48 |
Red blood cells were PRBCs and whole blood
| percentage of participants | Beriplex® P/N | Fresh Frozen Plasma |
|---|---|---|
| Percentage of Participants Who Received Red Blood Cells | 16.1 | 14.8 |
Number of participants with TEAEs. TEAEs were defined as adverse events that developed or worsened following exposure to investigational medicinal product. Treatment-related TEAEs were events whose relationship to study treatment was related, probably related, or possibly related in the opinion of the investigator. Treatment emergent adverse events with missing relationship were considered related to treatment. Serious TEAEs were treatment-emergent serious adverse events (SAEs).
| participants | Beriplex® P/N | Fresh Frozen Plasma |
|---|---|---|
| Any TEAE | 49 | 53 |
| At least possibly treatment-related TEAE | 8 | 15 |
| Serious TEAE | 22 | 23 |
| Death | 4 | 8 |
Collected over From the start of infusion up to the allowed time window of the Day 10 visit for non-serious AEs and from the start of infusion up to the allowed time window of the Day 45 visit for SAEs.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Beriplex® P/N | — | 22/88 (25%) | 41/88 (46.6%) |
| Fresh Frozen Plasma | — | 23/88 (26.1%) | 44/88 (50%) |
| Event | Beriplex® P/N | Fresh Frozen Plasma |
|---|---|---|
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 1/88 | 3/88 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 3/88 | 0/88 |
| PneumoniaInfections and infestations | 0/88 | 3/88 |
| Upper gastrointestinal haemorrhageGastrointestinal disorders | 2/88 | 0/88 |
| Acute myocardial infarctionCardiac disorders | 0/88 | 2/88 |
| SepsisInfections and infestations | 0/88 | 2/88 |
| AnaemiaBlood and lymphatic system disorders | 2/88 | 1/88 |
| Renal failure acuteRenal and urinary disorders | 2/88 | 0/88 |
| Pneumonia aspirationRespiratory, thoracic and mediastinal disorders | 1/88 | 1/88 |
| Acute pulmonary oedemaRespiratory, thoracic and mediastinal disorders | 0/88 | 1/88 |
| Event | Beriplex® P/N | Fresh Frozen Plasma |
|---|---|---|
| ConstipationGastrointestinal disorders | 10/88 | 4/88 |
| AnaemiaBlood and lymphatic system disorders | 9/88 | 9/88 |
| HypokalaemiaMetabolism and nutrition disorders | 7/88 | 8/88 |
| NauseaGastrointestinal disorders | 7/88 | 4/88 |
| HypotensionVascular disorders | 7/88 | 6/88 |
| Oedema peripheralGeneral disorders | 6/88 | 6/88 |
| Atrial fibrillationCardiac disorders | 5/88 | 3/88 |
| TachycardiaCardiac disorders | 5/88 | 1/88 |
| Pulmonary oedemaRespiratory, thoracic and mediastinal disorders | 1/88 | 5/88 |
| PyrexiaGeneral disorders | 3/88 | 5/88 |
The Intention-to-Treat Efficacy (ITT-E) population included all randomized participants who had received any study product, underwent the intended surgical procedure, and had an INR \> 1.3 prior to the infusion. Participants in the ITT-E population were analyzed 'as randomized'.
| Age, Customized(participants) | Beriplex® P/N | Fresh Frozen Plasma | Total |
|---|---|---|---|
| < 65 years | 32 | 39 | 71 |
| >= 65 to < 75 years | 21 | 19 | 40 |
| >= 75 years | 34 | 23 | 57 |
| Sex: Female, Male(Participants) | Beriplex® P/N | Fresh Frozen Plasma | Total |
|---|---|---|---|
| Female | 37 | 31 | 68 |
| Male | 50 | 50 | 100 |
The record gives a start of Feb 2009, a primary completion of Nov 2012 and a completion of Feb 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2014, 1 year 3 months after primary completion. A results delay was requested in Nov 2013.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Prothrombin complex concentrate · Four-factor Prothrombin Complex Concentrate